A Phase 3 interventional study of Psilocybin in Treatment Resistant Depression, sponsored by COMPASS Pathways. Completed at 40 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by COMPASS Pathways · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.
Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 2nd largest by enrollment, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 10th registered.
449 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
Centre Hospitalier St Anne · Sites in France
Ages 18+
Beersheva Mental Health Center · Sites in Israel
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University of Texas at Austin · Sites in United States
Ages 22–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 19 · Phase 3 3
First in 2019; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 258 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 30 across the 25 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 25 have an industry lead sponsor. The 10 most frequent:
COMPASS Pathways is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
COMPASS Pathways has 5 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
3 of the studies testing psilocybin in Depressive Disorder, Treatment-Resistant that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06731621Centre for Addiction and Mental HealthPsilocybin for Treatment-Resistant Depression in Autism | 2027-01 |
| NCT06518720Centre for Addiction and Mental HealthTreatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | 2027-03 |
| NCT07183748Beersheva Mental Health CenterPsilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
This is a phase III, international, multi-centre, randomised, parallel group, fixed single-dose, double-blind, placebo-controlled study. The study population will include participants aged ≥18 years with TRD.
Overall, 255 participants will be randomised in a 2:1 ratio to receive COMP360 25 mg or placebo.
The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week Screening Period.
Part A will include a six-week follow-up from initial investigational product (IP) administration.
In this study, the primary aim is to assess the efficacy and safety of a single dose of COMP360 25 mg versus placebo for reducing symptom severity in TRD, when administered with psychological support. This will be assessed in a 6-week, single-dose, double-blind, placebo-controlled part of the study (Part A). Durability of efficacy and long-term safety, and the efficacy and safety of re-treatment will be assessed in a 20-week single-dose, double-blind re-treatment part (Part B), and a 26-week open-label treatment part (Part C).
Key Inclusion Criteria:
Key Exclusion Criteria:
Psychiatric Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25 mg COMP360 Psilocybin
Drug: Psilocybin
Matched placebo
Drug: Psilocybin
COMP360 Psilocybin administered under supportive conditions
Also known as: COMP360
COMP360 25 mg versus placebo for the change from baseline in MADRS total score
Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity
Time frame: Week 6
COMP360 25 mg versus placebo for the change from baseline in SDS total score
Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.
Time frame: Week 6
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in May 2025, 28 months.
Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Depressive Disorder, Treatment-Resistant →
COMPASS Pathways